Oral asthma drug KT-621 tested for Long-Term safety

NCT ID NCT07677059

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study looks at the long-term safety and effectiveness of an oral drug called KT-621 in people with asthma. Participants have already completed a previous KT-621 asthma study. The goal is to see how well the drug works over time and if any side effects appear with longer use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

KT-621 (oral drug)

What this could lead to

If successful, this could show that KT-621 is a safe and effective long-term treatment option for controlling asthma.

What could go wrong

This is an extension study, not a new treatment test. It may reveal side effects that were not seen in the shorter parent study, and results may not apply to all asthma patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kymera Investigative Site

    RECRUITING

    Tampa, Florida, 33607, United States